Abstract Introduction Shrinking Lung Syndrome (SLS) is a rare complication of systemic lupus erythematosus (SLE) characterized by the development of dyspnea and in some cases, pleuritic chest pain. Workup often shows elevated diaphragm without parenchymal lung abnormalities, reduced lung volumes, and restrictive patterns on pulmonary function tests (PFTs). It has also been reported in other autoimmune diseases including rheumatoid arthritis, scleroderma, and Sjogren syndrome. Although various postulations have been made about the pathophysiology of SLS, its exact mechanism is still unknown. The prevalence is estimated to be around 1% and can occur at any point in the disease (Colquhoun 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK568683/ This abstract is funded by: None
Phayal et al. (Fri,) studied this question.